Absorption mechanism of hydroxysafflor yellow A in rats

Journal of China Pharmaceutical University

Volumn 37, Issue 4, 2006, Pages 312-317

  Zhang, Hai Fang ^a   Guo, Jian Xin ^a   Huang, Luo Sheng ^a   Ping, Qi Neng ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Absorption mechanism; Hydroxysafflor yellow A; Intestine transmit; P glycoprotein; Stability in vivo

Indexed keywords

CYCLOSPORIN A; ESSENTIAL OIL; GLYCOPROTEIN P; HYDROXYSAFFLOR YELLOW A; OLIVE OIL; PLANT EXTRACT; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG STABILITY; DUODENUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ILEUM; IN VIVO STUDY; INTESTINE TRANSIT TIME; JEJUNUM; NONHUMAN; RAT; RHIZOME; SAFFLOWER; SMALL INTESTINE ABSORPTION; STATISTICAL ANALYSIS; STOMACH; STOMACH ABSORPTION;

EID: 33746838451     PISSN: 10005048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. (Yang ZF), (Mei QB), (Jiang YP). (Northwest Pharm J), 2001,16(3):131-133.
2. (Li ZY), (Tu XH). (Tradit Chin Drug Res Clin Pharmacol), 2005, 16(2):153-156.
3. 2+ antagonistic activity of tinctormine[J]. Chem Pharm Bull, 1993,41(10):1 796-1 802.
4. (Liang H), (Fan JY), (Li AH), (Chin J Geriatr Heart Brain Vessel Dis), 2004,6(3):194-196.
5. (Zang BX), (Jin M), (Si N), (Acta Pharm Sin), 2002,37(9):696-697.
6. Zhu H, Wang Z, Ma C, et al. Neuroprotective effects of hydroxysafflor yellow A: in vivo and in vitro studies[J]. Planta Med, 2003,69(5):429-433.
7. Wei X, Liu H, Sun X, et al. Hydroxysafflor yellow A protects rat brains against ischemia-reperfusion injury by antioxidant action[J]. Neurosci Lett, 2005,386(1):58-62.
8. (Chen Q). Chinese source. 1993:335.
9. Mesia-Vela S, Souccar C. Pharmacological study of Stachytarpheta cayennensis Vahl in rodents[J]. Phytomedicine, 2004,11(7-8): 616-624.
10. (Qi R), (Ping QN), (Zhao W). (Acta Pharm Sin), 2003,38(12):953-956.
11. (Xiong QM), (Min Y), (Liu Y). (J Chin Med Ind), 2004,35(4):228-230.
12. (Liang WQ). Chinese source. 2000:14-16.
13. (Huang YZ). (Acta Pharm. Sin), 1988,23(6):426.
14. Varma MV, Ashokraj Y, Dey CS, et al. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement [J]. Pharmacol Res, 2003,48(4):347-359.
15. Hunter J, Hirst BH. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption[J]. Adv Drug Deliv Rev, 1997,25(2):129-157.
16. (Chen XJ), (Wang GJ). (J Chin Pharma Univ), 2003,34(6):483-496.